A record of what Sumeet Bagadia said publicly, with the source. Not advice.
“Recommends buying Aurobindo Pharma at ₹1,144, setting a stop-loss at ₹1,104, with a target price of ₹1,224. This call is based on a strong breakout observed in the stock.”
Sumeet Bagadia’s track record (trackable calls only): 1528 graded calls · 95% CI 32–37%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.
Entry: ₹1,144, as stated.
Target ₹1,224, stop ₹1,104, as stated.
No time frame is stated, so it is tracked until a close reaches ₹1,224 or ₹1,104: there is no fixed window.
The target ₹1,224 was reached on a close before the stop ₹1,104. Hit.
The grader’s working: R3 TRADE_SETUP: entered ₹1144 on 2025-11-04 (stated entry ₹1144, LEVEL_CMP entry, filled); target ₹1224 reached at close ₹1236.9 on 2025-11-17. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.
How it played out
How this is worked out- Target or stop first
- The target was reached on a close before the stop was.
- Time to target
- The target was reached on a close 8 trading sessions (13 calendar days) after the entry.
- Worst close against it
- The closing price went as far as 1.77% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.